Different pathways are involved in normal-tissue reaction after radiotherapy.
Combining different ‘omics’ techniques may identify critical pathways.
Functional assays may identify patient subgroups with different mechanisms.
A systems biology approach promises synergy from ‘omics’ and functional assays.